Categories
Diabetologia

Impact of pioglitazone on stroke outcomes: a real world database analysis

Morgan C L, Inzucchi S, Jenkins-Jones S, Puelles J, Currie C J. 07 May 2018

Categories
Diabetologia

Rates of hospital admission for hypoglycaemia by glucose-lowering regimen and by glycated haemoglobin status in people with type 2 diabetes

Holden S E, Jenkins-Jones S, Currie C J. 13 Sep 2016

Categories
Diabetologia

Survival as a function of HbA(1c) in people with type 2 diabetes using differing glucose-lowering regimens

Currie C J, Holden S E, Voss B, Rajpathak S, Alemayehu B, Williams D, Berni E R, Jenkins-Jones S, Engel S S. 13 Sep 2016

Categories
Diabetologia

Health service utilisation and costs of treatment with either exenatide twice daily or basal insulin for patients with type 2 diabetes: a retrospective UK study

Morgan C L, Jenkins-Jones S, Currie C J, Berni E R, Holden S E, Qiao Q. 09 Feb 2016

Categories
Diabetologia

Mortality after cancer among patients with diabetes mellitus: effect of diabetes duration and treatment: (questionable) classification of diabetic patients based on combination of specific glucose-lowering drugs

Holden S E, Bannister Ch A, Currie C J. 03 Jun 2014

Categories
Diabetologia

Combination therapy with metformin plus sulfonylureas versus metformin plus DPP-4 inhibitors and risk of all-cause mortality

Currie C J, Jenkins-Jones S, Mukherjee J, Morgan C L. 26 Apr 2014

Categories
Diabetologia

Exogenous insulin and risk of all-cause mortality in type 2 diabetes: a dose-response association

Holden S E, Schernthaner G, Jenkins-Jones S, Currie C J. 27 Sep 2013

Categories
Diabetologia

Association between first-line monotherapy with sulfonylurea versus metformin and risk of all-cause mortality

Jenkins-Jones S, Currie C J, Mukherjee J, Morgan C L. 16 Sep 2013

Categories
Diabetologia

ADVANCE and glycaemia thresholds: a need to clarify the statistical approach

Currie C J. 18 May 2012

Categories
Diabetologia

The longest ever randomised controlled trial of insulin glargine: study design and HbA1c findings

Currie C J. 07 Aug 2009

We use cookies to give you the best online experience. By agreeing you accept the use of cookies in accordance with our cookie policy.

Privacy Settings saved!
Privacy Settings

When you visit any web site, it may store or retrieve information on your browser, mostly in the form of cookies. Control your personal Cookie Services here.

These cookies are necessary for the website to function and cannot be switched off in our systems.

In order to use this website we use the following technically required cookies
  • wordpress_test_cookie
  • wordpress_logged_in_
  • wordpress_sec

Decline all Services
Accept all Services

MEET OUR BRANDS

About HDS

  • Our company
  • Boilerplate copy

HUMAN DATA SCIENCE

Logo
  • The HDS Logo
  • Logo mark
  • Clearspace
  • Backgrounds
Colours
  • Primary Palette
  • Secondary Palette

LIVINGSTONEIQ

Logo
  • The Livingstone Logo
  • Logo mark
  • Clearspace
  • Backgrounds
Colours
  • Primary Palette
  • Secondary Palette

PREVALENCEUK

Logo
  • The PrevalenceUK Logo
  • Logo mark
  • Clearspace
  • Backgrounds
Colours
  • Primary Palette
  • Secondary Palette

TYPOGRAPHY

  • Typestack

VOICE AND TONE

ICONS

  • Icon basics
  • Design considerations
  • Icon styles